Literature DB >> 8870024

Hypertensive diabetic rats in pharmacological studies.

P A Van Zwieten1, K L Kam, A J Pijl, M G Hendriks, O H Beenen, M Pfaffendorf.   

Abstract

Since hypertensive disease and diabetes frequently occur simultaneously there exists a requirement for animal models where both pathological entities are combined. The streptozotocin (STZ)-spontaneously hypertensive rat (STZ-SHR) and the obese Zucker rat are examples of animal models where hypertension and diabetes occur simultaneously. STZ-SHRs develop a hyperglycaemic syndrome, associated with other biochemical and morphological changes that to some extent approach insulin-dependent diabetes mellitus (type 1 diabetes) combined with hypertension. The obese (Fa/?) Zucker rat is characterized by the simultaneous occurrence of obesity, hyperglycaemia, hyperinsulinaemia, hyperlipidaemia and moderate hypertension. As such it approaches the patient with non-insulin-dependent diabetes mellitus (type 2 diabetes) who is simultaneously hypertensive. Lean (fa/fa) Zucker rats are suitable controls with respect to the obese animals. Both animal models (STZ-SHRs and obese Zucker rats) were characterized with respect to their biochemical, morphometric and haemodynamic properties. Both models were examined in particular with respect to the pharmacological characteristics of their cardiovascular system, as discussed in the present survey.

Entities:  

Mesh:

Year:  1996        PMID: 8870024     DOI: 10.1006/phrs.1996.0015

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  8 in total

1.  Impairment of long-term potentiation in the CA1, but not dentate gyrus, of the hippocampus in Obese Zucker rats: role of calcineurin and phosphorylated CaMKII.

Authors:  Korem H Alzoubi; Abdulaziz M Aleisa; Karim A Alkadhi
Journal:  J Mol Neurosci       Date:  2005       Impact factor: 3.444

2.  Hypoglycaemic and hypotensive effects of Ficus exasperata vahl. (Moraceae) leaf aqueous extract in rats.

Authors:  Stephen O Adewole; Tk Adenowo; Thajasvarie Naicker; John A O Ojewole
Journal:  Afr J Tradit Complement Altern Med       Date:  2011-04-02

3.  Palmitoylated prolactin-releasing peptide treatment had neuroprotective but not anti-obesity effect in fa/fa rats with leptin signaling disturbances.

Authors:  Lucia Mráziková; Silvie Hojná; Andrea Pačesová; Lucie Hrubá; Veronika Strnadová; Barbora Neprašová; Blanka Železná; Jaroslav Kuneš; Lenka Maletínská
Journal:  Nutr Diabetes       Date:  2022-05-19       Impact factor: 4.725

4.  Expression of gLTP in sympathetic ganglia of obese Zucker rats in vivo: molecular evidence.

Authors:  K H Alzoubi; A M Aleisa; K A Alkadhi
Journal:  J Mol Neurosci       Date:  2008-06-19       Impact factor: 3.444

Review 5.  Molecular mechanisms of urea transport in health and disease.

Authors:  Janet D Klein; Mitsi A Blount; Jeff M Sands
Journal:  Pflugers Arch       Date:  2012-09-25       Impact factor: 3.657

6.  A thrombospondin-1 antagonist of transforming growth factor-beta activation blocks cardiomyopathy in rats with diabetes and elevated angiotensin II.

Authors:  Souad Belmadani; Juan Bernal; Chih-Chang Wei; Manuel A Pallero; Louis Dell'italia; Joanne E Murphy-Ullrich; Kathleen H Berecek
Journal:  Am J Pathol       Date:  2007-07-19       Impact factor: 4.307

7.  Resveratrol prevents cardiovascular complications in the SHR/STZ rat by reductions in oxidative stress and inflammation.

Authors:  Rebecca K Vella; Candice Pullen; Fiona R Coulson; Andrew S Fenning
Journal:  Biomed Res Int       Date:  2015-02-23       Impact factor: 3.411

Review 8.  Combating Combination of Hypertension and Diabetes in Different Rat Models.

Authors:  Talma Rosenthal; Firas Younis; Ariela Alter
Journal:  Pharmaceuticals (Basel)       Date:  2010-03-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.